Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | GALR3 | O60755 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139081 | 0.94 | HDAC1 (0.50) | SMN1; SMN2MAPTLMNAMAPK1GALR3 | |
| SCHEMBL4138866 | 0.89 | HDAC1 (0.50) | SMN1; SMN2LMNAMAPK1HDAC1HIF1A | |
| SCHEMBL4137724 | 0.89 | NPC1 (0.50) | SMN1; SMN2MAPTLMNAMAPK1GALR3 | |
| SCHEMBL4443066 | 0.88 | LMNA (0.43) | SMN1; SMN2MAPTLMNAMAPK1GALR3 | |
| SCHEMBL4134697 | 0.87 | HIF1A (0.54) | SMN1; SMN2MAPTLMNAMAPK1HDAC1 | |
| SCHEMBL4138505 | 0.87 | MOK (0.46) | HIF1AEPAS1RAB9ANPC1KMT2A | |
| SCHEMBL4139048 | 0.87 | MOK (0.47) | MOKLRRK2 | |
| SCHEMBL4137644 | 0.87 | HIF1A (0.52) | SMN1; SMN2MAPTLMNAMAPK1HDAC1 | |
| SCHEMBL4144678 | 0.86 | HTR2C (0.48) | LMNAHDAC1ABL1BCRFLT3 | |
| SCHEMBL4151013 | 0.86 | BACE1 (0.52) | SMN1; SMN2MAPTLMNAMAPK1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | claimed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | claimed |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | UNIVERSITY OF SOUTH ALABAMA (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | UNIVERSITY OF SOUTH ALABAMA (US) | 2014-10-16 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| CN-101679308-B | Inhibitors of the hedgehog pathway | EXELIXIS INC | 2014-05-07 | — | — | CN | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| CN-101679308-A | inhibitors of the hedgehog pathway | EXELIXIS INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2134695-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | Exelixis, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | SHH, GLI1, SMO | SMN1; SMN2 3775/4885MAPT 3269/4885LMNA 4446/4885 |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | TP53, ANXA5, VHL | SMN1; SMN2 407/4885MAPT 4180/4885LMNA 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.